Pipeline Trigger: AeroRx $21M Series A Sparks CDMO Demand

🚀 Battle Card: AeroRx Therapeutics

• Ahmet Tutuncu, M.D., Ph.D., Co-Founder & CEO 📧 <ahmet.tutuncu@aerorxtx.com>

• Closing $21M accelerates inhalation combo therapy trials, creating immediate clinical ops and supply chain demands. Monitor this AeroRx Therapeutics sales trigger for new CDMO and CRO needs. → Source

• Navigating complex clinical trials for nebulized combination therapies

• Scaling specialized manufacturing and supply chain for inhalation products

• Primary: CDMO partnership for inhaled drug-device combination → scalable, compliant manufacturing

• Expansion: Clinical trial management CRO services → streamlined regulatory submissions and faster enrollment

• HQ: La Jolla, CA, USA

• Employees: ≈ 30

• Rev: Pre-revenue

• Website: [aerorxtx.com](https://aerorxtx.com/)

🤼 Competitive Intel

• Catalent — CDMO / Device Integration
• Unique edge: end-to-end formulation & nebulizer device combos
• Evaluated by Ops & Supply Chain for scale readiness

• Lonza — CDMO
• Unique edge: global regulatory support & large-scale capacity
• Evaluated by Supply Chain for compliance track record

• ICON — CRO
• Unique edge: respiratory trial expertise & patient recruitment
• Evaluated by Product Eng teams for trial design

• PPD — CRO
• Unique edge: full-service clinical ops with global footprint
• Evaluated by Clinical Dev leads for late-stage trials

✅ Do-Now Checklist

Next Step

🧠 Copy My Prompt for Personalized Cold Outreach

────────────────────────────
✏️ YOUR COMPANY
────────────────────────────
OUR_COMPANY   = ❑<your company>❑
OFFER_BRIEF   = ❑CDMO partnership for scalable inhaled drug-device manufacturing❑
PROOF_METRIC  = ❑30% faster manufacturing ramp❑
CTA_STYLE     = ❑quick_call❑
TONE          = ❑punchy❑

────────────────────────────
📌 TARGET COMPANY
────────────────────────────
NAME        = ❑Ahmet❑
COMPANY     = ❑AeroRx Therapeutics❑
DEPT        = ❑Ops & Supply Chain❑
SIZE        = ❑30❑
BOTTLENECK  = ❑scaling specialized manufacturing & supply chain❑
EVENT       = ❑Secures $21M Series A❑
DETAIL      = ❑closing of $21M Series A financing❑
PAIN        = ❑navigating complex clinical trials for nebulized combos❑
SRC         = ❑https://vcnewsdaily.com/aerorx-therapeutics/venture-capital-funding/qlxjqqgtxb❑
SIM_CO      = ❑≈ TBD❑
WIN_METRIC  = ❑≈ TBD❑
NEXT_SIZE   = ❑≈ 50❑
EMP_EST     = ❑≈ 30❑
REV_EST     = ❑≈ 0❑

────────────────────────
TASK FOR CHATGPT
────────────────────────
Role: “NewsletterForLeads SDR-Assist”.

Validate any ≈ guesses via SRC.

EMAIL  (keep breaks):
Subject: 30-person Ops & Supply Chain

Ahmet—noticed your Ops & Supply Chain team is ≈ 30.
That’s when scaling specialized manufacturing & supply chain slows growth.
We helped ≈ TBD fix this with CDMO partnership for scalable inhaled drug-device manufacturing.
Result: ≈ TBD.  
Quick call?

PS—next bottleneck hits ≈ 50.

DM ≤45 words, TONE:
Saw your post about closing of $21M Series A financing — navigating complex clinical trials for nebulized combos.  
CDMO partnership for scalable inhaled drug-device manufacturing. 30% faster manufacturing ramp.  
Quick chat?